Creative Biolabs plans webinar on 3D human brain models for neurodegeneration research

Creative Biolabs will host a free webinar on July 14, 2026, featuring Mount Sinai neuroscientist Joel W. Blanchard and new approaches to engineered human 3D brain tissues. The event is aimed at researchers and drug developers looking for more human-relevant models of Alzheimer’s, Parkinson’s and related diseases.

Why it matters: - Alzheimer’s disease, Parkinson’s disease and related dementias still lack preclinical models that fully reflect human brain biology. - The webinar will focus on 3D human brain systems that could improve disease modeling, biomarker discovery, toxicity evaluation and therapeutic target identification. - Better human-relevant models could help narrow the gap between lab findings and clinical translation in CNS drug development.

What happened: - Creative Biolabs announced a free virtual webinar titled “Engineered Human 3D Brain Tissues for Neurodegenerative Disease Modeling: From Genetic Risk to Therapeutic Opportunity.” - The event is scheduled for July 14, 2026, at 10:00 AM EDT. - Guest speaker Joel W. Blanchard, PhD, an associate professor at the Icahn School of Medicine at Mount Sinai, will present his lab’s work on multicellular, stem cell-derived 3D human brain tissues. - Creative Biolabs is marketing the event to academic researchers, biopharmaceutical R&D professionals and scientists working in neurodegeneration and CNS drug development.

The details: - The webinar will examine how engineered human 3D brain tissues can model neurodegeneration in a more physiologically relevant human context. - The presentation will address limitations of traditional 2D cell cultures and animal models, especially for studying genetic vulnerability, glial dysfunction, cerebrovascular remodeling and blood-brain barrier disruption. - Dr. Blanchard will discuss a rare genetic mutation linked to juvenile Parkinson’s disease and the lysosome-polyamine-epigenetic axis. - The talk will also cover APOE4, α-synuclein co-pathology, glial dysfunction and blood-brain barrier disruption in Alzheimer’s disease. - The webinar will highlight organoid and brain-on-a-chip approaches for biomarker discovery, toxicity testing and precision medicine. - Creative Biolabs said the event is intended to help teams find actionable therapeutic targets. - The registration page is available on Creative Biolabs' website.

Between the lines: - The announcement reflects growing interest in 3D biology platforms as substitutes for simplified preclinical systems that often miss human disease complexity. - The focus on genetic risk, neuro-immune-vascular interactions and tissue engineering points to a broader push in neuroscience toward models that can better predict drug response. - Creative Biolabs is positioning its webinar series and platform offerings around translational research needs, not just basic science.

What's next: - Researchers and drug developers can register for the July 14 session to hear the technical presentation and practical applications. - Creative Biolabs is likely to use the webinar to showcase its 3D biology products and services, including spheroid models, organoids, organ-on-a-chip models and precision-cut tissue slices. - The company says its broader goal is to support biomarker discovery, toxicity evaluation and disease modeling in global biomedical research.